Ane Gerda Zahl Eriksson
Gynecologic Oncology Group, Memorial Sloan Kettering Cancer Center, Oslo University Hospital
Papers
6
Total Citations
360
H-Index
5
About
Ane Gerda Zahl Eriksson is a leading clinical researcher in gynecologic oncology, whose work has fundamentally advanced the surgical management of uterine and cervical cancers. Her research focuses on three critical areas: the implementation of robotic-assisted surgery, the optimization of sentinel lymph node (SLN) mapping, and the impact of obesity on surgical outcomes. Dr. Eriksson’s most impactful contribution is the landmark RACC trial (150 citations), an international multi-center randomized controlled trial that established the safety and efficacy of the robot-assisted approach for cervical cancer. She has also made seminal contributions to SLN mapping in uterine cancer, demonstrating the superiority of indocyanine green with near-infrared fluorescence over blue dye (50 citations) and systematically addressing the challenges of mapping in obese patients (98 and 53 citations). Her work provides crucial evidence for cost-effective, minimally invasive staging, including a recent cost-effectiveness analysis of SLN biopsy in high-risk endometrial carcinoma. Through these high-impact studies, Dr. Eriksson has directly shaped international surgical guidelines, improving outcomes for women with gynecologic malignancies.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4
- 5
- 6